EADV News: Bimekizumab Shows Long-Term Efficacy and Safety in HS
Bimekizumab (Bimzelx, UCB) improves clinical response, symptoms, severity, and quality of life in patients with hidradenitis suppurativa (HS) and results last up to two years, according to data from Phase 3 studies, BE HEARD I and BE HEARD II, and their open-label extension presented at the European Academy of Dermatology and Venereology (EADV) Congress in […]